Weekly oral idarubicin in advanced prostatic cancer. A phase II study.
Twenty-five patients with advanced prostatic cancer progressing after one course of endocrine treatment entered a phase II study of weekly administration of 30 mg Idarubicin orally. Twenty-two patients were evaluable for response and partial response (PR) was noted in 2 patients and stable disease (NC) in 10 patients. Median survival was 31 weeks and median time to progression was 14 weeks. Twenty-three patients were eligible in a score system combining analgetic consumption and pain reduction measured on a Visual Analogue Scale (VAS) and 30% achieved a subjective response. Fifteen patients fulfilled treatment with the planned dose and 10 patients had dose reduction to a median of 23.8 mg Idarubicin. Haematological toxicity was greater than or equal to grade 3 (WHO) in 20% of the patients. Non-haematological toxicity was dominated by nausea/vomiting with 48% grade 3 (WHO). In conclusion, Idarubicin seems of limited value in the treatment of patients refractory to first line endocrine treatment.
Madsen
E L
EL
Department of Oncology R, Odense University Hospital, Denmark.
Bastholt
L
L
Bertelsen
K
K
Rose
C
C
Nielsen
E S
ES
Gadeberg
C C
CC
D000284:Administration, Oral; D000368:Aged; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010146:Pain / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012074:Remission Induction
D015255:Idarubicin